Gain the latest insights from our cross-functional Advisory experts on:  

New administration impact planning

• Summarizing early actions of the Trump administration and forecasting impacts on drug pricing
• Medicare Advantage
• Part D policies for 2026 and beyond

HEOR and Real-World Evidence (RWE)

• Conducting RWE studies by analyzing real-world data, including closed/open claims, electronic medical records, labs, and other novel data sources
• Engaging with patients and caregivers to understand preference and the indirect burden of disease
• Building economic models to support payer engagement and regulatory submissions
• Collaborating with manufacturers to develop RWE generation plans and data strategy
• Advising on evidence strategy and evidence generation in preparation for Medicare drug price negotiation

Commercial analytics

• Analyzing utilization and patients-in-play
• Assessing the effects of Part D smoothing on patient out-of-pocket costs and creating strategies to use those effects to support access to care
• Modeling average sales price in Part B and implications for both payers and providers; assessing and mitigating impacts of 340B
• Analyzing books of business for Commercial, Exchange, and Employer health plans as well as High Deductible Health Plans and Health Reimbursement Arrangements, and developing strategies tailored to each plan type

Launch and lifecycle management – understanding the payer lens

• Advising on indication sequencing
• Refining payer value propositions
• Supporting traditional launch activities as well as compendia and guideline access strategies

Access Marketing

• Combining industry-leading capabilities of market access strategy with brand marketing innovation to improve engagement with key payer customers

Meet our team at AMCP

Michael Ciarametaro, Managing Director, Policy: Michael provides strategic advice to life sciences clients on developing value and evidence strategy and navigating the Inflation Reduction Act (IRA), drug pricing, and payment reform. 

Taylor Schwartz, Managing Director, Evidence and Strategy: Taylor works collaboratively with clients to develop, design, and execute epidemiological and health economics and outcomes research studies in a variety of therapeutic areas, in addition to health policy analyses and medical innovation value assessment studies. 

John Neal, Managing Director: John partners with pharmaceutical and biotechnology clients to develop market access assessments and launch strategies to ensure successful asset commercialization.